Audience
Type
Conditions
Procedures
Other
Results
20 July 2022
Presentations, Videos & Papers
ACPGBI 2022 Annual Meeting
Recordings of sessions from Day 1 of the 2022 ACPGBI Annual Meeting, Edinburgh
*Please note that this does not include recordings from the sponsored sessions
22 June 2022
Presentations, Videos & Papers
The 3rd and final webinar in the interactive case-based Emergency Colorectal Surgery series was held on June 20th. This was again hosted by the EGS Subcommittee and chaired by Richard Guy with an invited panel made up of six Colorectal Consultant Surgeons (Gill Tierney, Andy Miller, Dominic Slade, Jim Tiernan) and Sue Blackwell, PLG representative on the EGS Subcommittee.
Topics covered included intestinal ischaemia, anastomotic leak, abdominal catastrophe, stoma complications and the open abdomen and the webinar seems to have been popular and well-received.
The overall purpose once again was to publicise the ACPGBI Guidelines on Emergency Colorectal Surgery and so we were particularly pleased that Andy Miller, who was principal author and past-Chair of the EGS Committee, could join us all the way from New Zealand at such an early hour for him!
1 June 2022
Consensus Statements and Guidelines
Authors (Guideline development group (GDG))
Kevin J Monahan / Michael M. Davies (Co-chairs, and lead authors). Co-authors: Muti Abulafi, Ayan Banerjea, Brian Nicholson, Ramesh Arasaradnam, Neil Barker, Sally Benton, Richard Booth, David Burling, Rachel Carten, Nigel D’Souza, James East, Jos Kleijnen, Michael Machesney, Maria Pettman, Jenny Pipe, Lance Saker, Linda Sharp, James Stephenson, Robert Steele.
18 May 2022
Presentations, Videos & Papers
Following the success of the first case-based interactive Emergency Colorectal Surgery, we will be holding the second one in the series on Monday May 16th at 7pm, discussing further exciting surgical challenges, such as intestinal ischaemia and inflammatory bowel disease, with our panel of experts.
2 May 2022
Consensus Statements and Guidelines
This is the second of a series of two articles reporting the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis [UC]. The first article is focused on medical management, and the present article addresses medical treatment of acute severe ulcerative colitis [ASUC] and surgical management of medically refractory UC patients, including preoperative optimisation, surgical strategies, and technical issues. The article provides advice for a variety of common clinical and surgical conditions. Together, the articles represent an update of the evidence-based recommendations of the ECCO for UC.
2 May 2022
Consensus Statements and Guidelines
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic inflammation extending to a variable extent from the rectum. Care of the patient with UC requires appropriate input from across the multiprofessional team. These guidelines summarise the recommended medical treatment for adults with UC. Other ECCO guidelines consider the approach to UC diagnosis and monitoring,1–3 nursing care,4 management of disease complications,5–7 risk of infection,8 and technical aspects of surgery.9 This document was prepared as part of a process that also led to the publication of a related guideline with recommendations on the surgical care of the patients with UC and on the medical aspects of the management of the patient hospitalised with severe UC. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.
2 May 2022
Consensus Statements and Guidelines
“The British Intestinal Failure Alliance (BIFA) is a multi-professional special interest group within the British Association for Parenteral and Enteral Nutrition (BAPEN). It focuses on temporary/reversible intestinal failure (IF) (Type 2 IF) and patients needing home parenteral support (nutrition and/or fluid) (Type 3 IF). The guidelines/recommendations and the position statements have all been written by the named authors and revised by the BIFA committee and BAPEN council. They aim to help staff working with patients with IF and those needing parenteral support.”
2 May 2022
Consensus Statements and Guidelines
The introduction and broad use of new immunosuppressive agents, including biologic agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease [IBD] in recent decades. With such immunosuppression, the potential for opportunistic infection is a key safety concern. Opportunistic infections pose particular problems for the clinician; they are potentially serious, often difficult to recognise, associated with appreciable morbidity or mortality, and are challenging to treat effectively. The first guideline on opportunistic infections was published in 20091 followed by an update in 2014.2 New evidence in this field and in vaccination strategies for immunosuppressed IBD patients led the European Crohn’s and Colitis Organization [ECCO] to update the previous consensus on opportunistic infections in IBD. The current document is focused on viral, mycobacterial, bacterial, fungal, and parasitic infections and on vaccination strategies for immunosuppressed IBD patients. The target audience includes IBD specialists, gastroenterologists, surgeons, and paediatricians.
2 May 2022
Consensus Statements and Guidelines
This article is the second in a series of two publications relating to the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the management of Crohn’s disease. The first article covers medical management; the present article addresses surgical management, including preoperative aspects and drug management before surgery. It also provides technical advice for a variety of common clinical situations. Both articles together represent the evidence-based recommendations of the ECCO for Crohn’s disease and an update of previous guidelines.
2 May 2022
Consensus Statements and Guidelines
Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability.1 CD can affect individuals of any age, from children to the elderly,2,3 and may cause significant morbidity and impact on quality of life. Up to one-third of patients present with complicated behaviour [strictures, fistula, or abscesses] at diagnosis.4 Most patients over time will develop a complication, with roughly 50% of patients requiring surgery within 10 years of diagnosis.5–7 As the precise aetiology of CD remains unknown, a curative therapy is not yet available.8 Several agents are available for the medical treatment of CD. Medical agents include mesalazine [5-ASA], locally active steroids [such as budesonide], systemic steroids, thiopurines such as azathioprine [AZA] and mercaptopurine [MP], methotrexate [MTX], and biologic therapies (such as anti-tumour necrosis factor [TNF], anti-integrins, and anti-interleukin [IL] 12/23].